Ketobemidone: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
Rabin Bista (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{drugbox | | {{drugbox | | ||
| IUPAC_name = 1-[4-(3-hydroxyphenyl)-1-methyl-4-piperidyl]propan-1-one | | IUPAC_name = 1-[4-(3-hydroxyphenyl)-1-methyl-4-piperidyl]propan-1-one | ||
| image = | | image = Ketobemidone Wiki Str.png | ||
| width = 180 | | width = 180 | ||
| CAS_number = 469-79-4 | | CAS_number = 469-79-4 | ||
| Line 26: | Line 26: | ||
| routes_of_administration = Oral, rectal, [[intravenous therapy|intravenous]] | | routes_of_administration = Oral, rectal, [[intravenous therapy|intravenous]] | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
== Overview == | |||
'''Ketobemidone''' is a powerful [[opioid]] [[analgesic]]. Its potency is equal to [[morphine]], and it also has some [[NMDA]]-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. | '''Ketobemidone''' is a powerful [[opioid]] [[analgesic]]. Its potency is equal to [[morphine]], and it also has some [[NMDA]]-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. | ||
| Line 73: | Line 73: | ||
==References== | ==References== | ||
{{Reflist|2}} | |||
{{Analgesics}} | {{Analgesics}} | ||
Latest revision as of 16:03, 9 April 2015
 | |
| Clinical data | |
|---|---|
| Synonyms | Ketobemidone, Cliradon, Cymidon, Ketogan, Ketorax |
| Routes of administration | Oral, rectal, intravenous |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 34% (oral), 44% (rectal) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C15H21NO2 |
| Molar mass | 247.333 g/mol |
|
WikiDoc Resources for Ketobemidone |
|
Articles |
|---|
|
Most recent articles on Ketobemidone Most cited articles on Ketobemidone |
|
Media |
|
Powerpoint slides on Ketobemidone |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Ketobemidone at Clinical Trials.gov Clinical Trials on Ketobemidone at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Ketobemidone
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Ketobemidone Discussion groups on Ketobemidone Patient Handouts on Ketobemidone Directions to Hospitals Treating Ketobemidone Risk calculators and risk factors for Ketobemidone
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Ketobemidone |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ketobemidone is a powerful opioid analgesic. Its potency is equal to morphine, and it also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids.
It is used for all types of severe pain, such as postoperative, cancer, kidney stones and fractures.
History
It was first synthesized in 1942 by Eisleb. The first study of it in man was published in 1946, and it was introduced in clinical medicine shortly after.
Chemistry
Ketobemidone is 1-methyl-4-(3-hydroxyphenyl)-4-propionylpiperidine. It is usually available as the hydrochloride, which is a white powder. It is synthesized by alkylating (3-methoxyphenyl)acetonitrile with bis(2-chloroethyl)methylamine, followed by reaction with ethylmagnesiumbromide, and finally O-demethylation with hydrobromic acid.
Pharmacology
Experiments on former addicts indicated it was more addictive than other opioids, so in 1954 the Economic and Social Council took a resolution urging governments to stop manufacture and use of ketobemidone[1] . As a result ketobemidone is mostly used in the Scandinavian countries, with Denmark topping the statistics[2] . This result was not in agreement with clinical observations, and another study in 1958 didn't find it more addictive than morphine[3]. That study noticed that while for morphine the dose for euphoria is the same as that for analgesia, for ketobemidone the analgesic dose was well below the euphoric dose.
Analgesia after 5-10 mg orally or 5-7.5 mg intravenously lasts 3-5 hours. Ketobemidone is also available in preparations with a spasmolytic, which can improve the analgesia.
Ketobemidone is mainly metabolised by conjugation of the phenolic hydroxyl group, and by N-desmethylation. Only about 16% is excreted unchanged.
Pfizer manufactures ketobemidone under the tradenames Ketogan and Ketorax. It is available as tablets, suppositories and injection fluid. A sustained release formulation exists sold as Ketodur in some countries containing 10 or 25 mg ketobemidone.
References
- ↑ UNODC. "Development of Synthetic Narcotic Drugs". Retrieved 2006-09-07.
- ↑ INCB. "Statistical information on narcotic drugs" (PDF). Retrieved 2006-09-07.
- ↑ Bondesson, Ulf (1982). "Biological fate of ketobemidone in man". Abstracts of Uppsala dissertations from the Faculty of Pharmacy. 68.
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Opioids
- Drugs